Iso-Osmolar Iodixanol Induces Less Increase in Circulating Endothelial Microparticles In Vivo and Less Endothelial Apoptosis In Vitro Compared with Low-Osmolar Iohexol

Contrast Media & Molecular Imaging
Beijian ZhangShu Meng

Abstract

There is no consensus on whether iodixanol is superior to iohexol. This study aimed to compare the effects of iodixanol and iohexol on circulating endothelial microparticles (EMPs) in stable coronary artery disease (CAD) patients with diabetes mellitus (DM), and also their cytotoxic effects on human umbilical vein endothelial cells (HUVECs) in vitro. 100 CAD patients with DM were randomly assigned to receive iso-osmolar contrast medium iodixanol (group I) or low-osmolar iohexol (group II) during coronary angioplasty. An additional 49 CAD patients without DM receiving iohexol were recruited as group III. Circulating CD31+/CD41a- EMPs, CD62E+ EMPs, and CD31+/CD41a+ platelet microparticles (PMPs) were determined by flow cytometry. In vitro, the cytotoxic effects of iodixanol and iohexol on HUVECs were determined. Circulating CD31+/CD41a- EMPs and PMPs were significantly increased after angioplasty in all 3 groups, while CD62E+ EMPs significantly decreased in group I. CD31+/CD41a- EMPs and PMPs were significantly higher in group II than group I or III. In vitro, both contrast media induced EMP release and inhibited the viability and induced apoptosis of HUVECs, as well as increasing Bax and cleaved caspase-3 and decreasing Bcl-2. T...Continue Reading

References

Oct 2, 2001·International Journal of Cardiology·A Flinck, B Gottfridsson
Oct 3, 2003·Journal of the American College of Cardiology·Michael E WidlanskyJoseph A Vita
Feb 24, 2004·Frontiers in Bioscience : a Journal and Virtual Library·Lawrence L HorstmanYeon S Ahn
May 2, 2006·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Claude Le FeuvreJean P Metzger
Jun 21, 2006·The American Journal of Cardiology·Roque B ArteagaYeon S Ahn
Aug 15, 2006·Journal of the American College of Cardiology·Peter A McCulloughFulvio Stacul
Mar 14, 2007·Circulation·John E DeanfieldTon J Rabelink
Jul 17, 2010·Mediators of Inflammation·A F TramontanoL Ragolia
Dec 28, 2010·European Heart Journal·Jan-Malte SinningNikos Werner
May 14, 2011·Circulation Research·A Phillip Owens, Nigel Mackman
Aug 20, 2011·Circulation Research·Pierre-Emmanuel RautouChantal M Boulanger
Oct 19, 2012·American Journal of Physiology. Renal Physiology·William H Beierwaltes
Oct 23, 2012·Vascular Pharmacology·Egeria ScodittiMaria Rosa Montinari
May 16, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Natalie G LumsdenJaye P F Chin-Dusting
Jan 15, 2014·International Journal of Cardiology·Shiqun SunBen He
May 14, 2016·Thrombosis and Haemostasis·Francesca SantilliGiovanni Davì
Oct 21, 2016·Clinical and Experimental Pharmacology & Physiology·Osamu KuriharaWataru Shimizu
May 10, 2017·Mechanisms of Ageing and Development·Cesar SepúlvedaEduardo Fuentes
May 13, 2017·Circulation Research·Dilyana TodorovaFrançoise Dignat-George

❮ Previous
Next ❯

Citations

Dec 14, 2021·Frontiers in Cell and Developmental Biology·Liuhua ZhouLiansheng Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
fluorescence microscopy

Software Mentioned

Image Lab
CytExpert
SPSS

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis